ReviewInnere Medizin (Heidelberg, Germany)2026
[Cardiovascular magnetic resonance imaging: routine use in cardiology and unique strengths].
Review in Innere Medizin (Heidelberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular magnetic resonance (CMR) has evolved over the past two decades into a central component of modern cardiology diagnostics. Its particular strength lies in the unique combination of highly accurate functional assessment and non-invasive tissue characterization within a single examination. The indications for CMR in contemporary clinical practice are broad. In the evaluation of coronary artery disease, stress perfusion CMR enables reliable assessment of myocardial ischemia and complements this with simultaneous viability analysis using late gadolinium enhancement (LGE). In inflammatory myocardial diseases, CMR, based on the Lake Louise criteria, allows differentiation between acute and chronic injury and supports therapeutic decision-making. In the assessment of unexplained left ventricular hypertrophy, CMR provides decisive insights for differential diagnosis through mapping techniques and characteristic tissue patterns, for example in amyloidosis or hypertrophic cardiomyopathy. It also plays a key role in heart failure by contributing to etiological clarification and prognostic assessment. Additional important applications include genetic and arrhythmogenic cardiomyopathies, where CMR enables detailed evaluation of morphology, biventricular function, and fibrofatty myocardial remodeling, as well as valvular heart disease, where it allows precise quantification of regurgitant volumes, flow, and ventricular volumes, particularly when echocardiography is limited. Further indications include cardiac masses, congenital heart disease, and transplant cardiology. Overall, CMR provides an integrated, precise, and non-invasive diagnostic approach that reduces diagnostic uncertainty, improves risk stratification, and supports clinical decision-making. Future developments, particularly in quantitative imaging, standardization, and the generation of robust clinical evidence, are expected to further strengthen its role in clinical care. This article follows an indication-based approach and provides practical guidance on clinical scenarios in which CMR should be considered.
Indexed as
Identifiers
42420516What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.